Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Carmona joins MedWise campaign

This article was originally published in The Tan Sheet

Executive Summary

New print ads on OTC safety feature Surgeon General Richard Carmona, MD, "speaking" to consumers about OTC medicines, the National Council on Patient Information & Safety announces March 8. The campaign, initially launched last fall by NCPIE and FDA, presents Carmona's "prescription" for taking OTCs, including questions for health care providers on what OTCs are available for certain conditions and how often the drugs should be taken (1"The Tan Sheet" Sept. 15, 2003, p. 8). Full-, half-, and quarter-page ads will be sent to health journals and pharmacy organizations to be distributed to senior and community centers. In addition, national radio spots in English and Spanish will warn against taking more than one OTC at a time with the same active ingredient...

You may also be interested in...



“MedWise Prescription” Education Campaign Targets Rx-OTC Interactions

The latest "MedWise" consumer education campaign will focus on warning patients against the potential for overdosing when mixing OTC and prescription drugs with the same active ingredients

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096575

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel